Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

RARE PHOTOS: Ntla | Vintage Vibes

Should You Buy the Dip in Intellia Therapeutics Stock?

A patient’s death shook Intellia Therapeutics and sank its stock. Should investors buy the dip or steer clear?

Barchart

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles

Intellia Therapeutics Inc. (NASDAQ:NTLA) shares tumbled after the company said it had temporarily paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of its experimental CRISPR therapy, nexiguran ziclumeran (nex-z), following a serious liver-related adverse event in one participant.

Benzinga

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Intellia Therapeutics Shares Are Ripping Higher: Here's Why

Intellia Therapeutics Inc (NASDAQ:NTLA) shares are soaring on Thursday after the company completed enrollment in its crucial Phase 3 HAELO trial and laid out its key development milestones.

Benzinga

Cathie Wood Is Betting Big on Intellia Therapeutics. Should You Buy NTLA Stock Here?

Cathie Wood recently acquired shares of the biotech company. Should you do the same?

Barchart

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook

Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.

MarketBeat

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

This clinical-stage biotech stock has a strong pipeline capable of creating the next Moderna.

Barchart

Read news from The Economist, FT, and more,
with one subscription

This Cathie Wood Stock Can Soar 221%, Says Wall Street

Promising clinical trial results have analysts optimistic about the company’s future.

Barchart

3 Cathie Wood Biotech Stocks That Analysts Expect to Double

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference for Wood's disruptive approach to investing, may find these stocks particularly compelling.

Barchart

Call for port extension to be halted as genocide remains are found on Namibia’s Shark Island

Researchers say more bodies of Herero and Nama people from early 20th century concentration camp could be in waters around port

The Guardian - UK

Cathie Wood Is Loading up on These 5 Stocks -- Should You?

Cathie Wood’s ETFs have hit a rough patch this year amid volatile market conditions caused by sky-high inflation and the Fed’s hawkish tilt. Moreover, the stock market is expected to remain under pressure in the coming months since the central bank intends to keep hiking rates. So, we think it…

StockNews.com

Intellia's Gene-Editing Candidate Shows Durability In ATTR Amyloidosis

Intellia Therapeutics Inc (NASDAQ:NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced additional interim data from the Phase 1 study of NTLA-2001, in vivo genome editing candidate for transthyretin (ATTR) amyloidosis. Intellia had said that at the highest dose level (1.0mg/kg), six patients had shown a 93% mean reduction in the toxic protein. In the new data,…

Benzinga

BMO Initiates Coverage On This Gene Editing Spearhead

BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price. The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies. But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ:EDIT), and high patient…

Benzinga

4 Genomics Stocks to Consider Buying After the Crash

The genomics industry is poised to grow significantly in 2022, driven by strong demand amid the increasing need for personalized medicine and the rising population with serious illnesses. Thus, beaten-down genomics stocks Invitae (NVTA), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and CRISPR Therapeutics (CRSP) could be ideal investments now.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

5 Cathie Wood Stocks That Remain Overvalued Despite the Market Correction

Cathie Wood stocks have been foundering for the past few months owing to volatile market conditions caused in-part by aggressive Federal Reserve interest rate hikes. So, given their companies’ bleak financials and relative overvaluation, we think it could be wise to avoid popular Cathie Wood stocks Roku (ROKU), Teladoc (TDOC),…

Benzinga

How To Attend Intellia Therapeutics Q1 2022 Earnings Conference Call

Intellia Therapeutics (NASDAQ:NTLA) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.

StockNews.com

5 Beaten-Down Biotech Stocks Cathie Wood Loves

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022, supported by strong demand for healthcare and medical products and increasing investments in R&D. Given these factors, Wall…

Benzinga

Here's How Much $100 Invested In Intellia Therapeutics 5 Years Ago Would Be Worth Today

Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 19.59% on an annualized basis.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer

Intellia Therapeutics Inc's (NASDAQ: NTLA) CRISPR-powered T cell therapy has

Benzinga

Analyst Ratings For Intellia Therapeutics

Over the past 3 months, 4 analysts have published their opinion on Intellia Therapeutics (NASDAQ:NTLA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

$100 Invested In This Stock 5 Years Ago, Would Be Worth This Much

Intellia Therapeutics (NASDAQ:NTLA) has outperformed the market over the past 5 years by 33.15% on an annualized basis.

Benzinga

Analyst Ratings For Intellia Therapeutics

Analysts have provided the following ratings for Intellia Therapeutics (NASDAQ:NTLA) within the last quarter:

People

Cathie Wood

652 stories

Mangeet Kaur BounsMangeet

595 stories

David Kostin

16 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.